Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved

Abstract Background Frailty is a severe, common co‐morbidity associated with heart failure (HF) with preserved ejection fraction (HFpEF). The impact of frailty on HFpEF outcomes may affect treatment choices in HFpEF. The impact of frailty on HFpEF patients and any impact on the clinical benefits of...

Description complète

Détails bibliographiques

Auteurs principaux:	Andrew J.S. Coats, Javed Butler, Hiroyuki Tsutsui, Wolfram Doehner, Gerasimos Filippatos, João Pedro Ferreira, Michael Böhm, Vijay K. Chopra, Subodh Verma, Matias Nordaby, Tomoko Iwata, Daisuke Nitta, Piotr Ponikowski, Faiez Zannad, Milton Packer, Stefan D. Anker
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2024-02-01
Collection:	Journal of Cachexia, Sarcopenia and Muscle
Sujets:	empagliflozin frailty heart failure with preserved ejection fraction randomized clinical trial SGLT2 inhibitors
Accès en ligne:	https://doi.org/10.1002/jcsm.13393
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!